PAR1-mediated NFκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism

Journal of Cellular Biochemistry

Volumn 96, Issue 3, 2005, Pages 641-652

  Tantivejkul, Kwanchanit ^a,c   Loberg, Robert D ^a   Mawocha, Samkeliso C ^a   Day, Lashon L ^a   St John, Lauren ^a   Pienta, Brian A ^a   Rubin, Mark A ^b   Pienta, Kenneth J ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bcl xL; Cytokines; PAR1; Prostate cancer; Survival

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DNA; DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEINASE ACTIVATED RECEPTOR 1; SB 203589; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL X; TAXOID; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DRUG RESISTANCE; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; SIGNAL TRANSDUCTION; BIOPSY; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN MICROARRAY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BIOPSY; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; ENZYME ACTIVATION; HUMANS; IN SITU NICK-END LABELING; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; TAXOIDS; TRANSCRIPTION FACTOR RELA;

EID: 27144507922     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20533     Document Type: Article

References (44)

1. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. 1999. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 18:7423-7431.
2. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M. 2004. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60:153-159.
3. Chalmers CJ, Balmanno K, Hadfield K, Ley R, Cook SJ. 2003. Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. Biochem J 375:99-109.
4. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ. 2002. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60: 760-765.
5. Coughlin SR. 1999. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96:11023-11027.
6. Deocampo ND, Huang H, Tindall DJ. 2003. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 28:145-153.
7. Dhanasekaran SM, Barrette TR, Ghosh D1 Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
8. Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R. 2001. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 276:10952-10962.
9. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. 1994. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063-3070.
10. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. 2001. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 86:1094-1098.
11. Je JH, Lee JY, Jung KJ, Sung B, Go EK, Yu BP, Chuhg HY. 2004. NF-kappaB activation mechanism of 4-hydroxy-hexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett 566:183-189.
12. Kang KW, Choi SY, Cho MK, Lee CH, Kim SG. 2003. Thrombin induces nitric-oxide synthase via Galpha12/ 13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation. J Biol Chem 278:17368-17378.
13. Karin M, Cao Y, Greten FR, Li ZW. 2002. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2:301-310.
14. Kaur J, Woodman RC, Kubes P. 2003. P38 MAPK: Critical molecule in thrombin-induced NF-kappa B-dependent leukocyte recruitment. Am J Physiol Heart Circ Physiol 284:H1095-H1103.
15. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ. 2001. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3:33-42.
16. Kohli M, Fink LM, Spencer HJ, Zent CS. 2002. Advanced prostate cancer activates coagulation: A controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 13:1-5.
17. Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Ciftcioglu A, Gulkesen KH, Ozes NO, Baykara M, Luleci G, Sanlioglu S. 2004. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 22:307-312.
18. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. 2000. Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity. Cancer Res 60: 6052-6060.
19. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. 2003. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22:7809-7818.
20. Lidington EA, Haskard DO, Mason JC. 2000. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 96:2784-2792.
21. Lind SE, Caprini JA, Goldshteyn S, Dohnal JC, Vesely SK, Shevrin DH. 2003. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost 89:185-189.
22. Liu J, Bastian M, Kohlschein P, Schuff-Werner P, Steiner M. 2003. Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. Urol Res 31:163-168.
23. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV. 2004. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101:7112-7117.
24. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. 2002. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 30:173-177.
25. Marin V, Farnarier C, Gres S, Kaplanski S, Su MS, Dinarello CA, Kaplanski G. 2001. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood 98:667-673.
26. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, Yang Z. 2004. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: Implications for atherosclerotic endothelial dysfunction. Circulation 110:3708-3714.
27. Mitsui H, Maruyama T, Kimura S, Takuwa Y. 1998. Thrombin activates two stress-activated protein kinases, c-Jun N-terminal kinase and p38, in HepG2 cells. Hepatology 27:1362-1367.
28. Nierodzik ML, Kajumo F, Karpatkin S. 1992. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52:3267-3272.
29. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. 1999. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18:7389-7394.
30. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. 2004. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 60:120-129.
31. Rahman A, True AL, Anwar KN, Ye RD, Voyno-Yasenetskaya TA, Malik AB. 2002. Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. Circ Res 91:398-405.
32. Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y. 2004. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 61:105-113.
33. Rubin MA, Dunn R, Strawderman M, Pienta KJ. 2002. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312-319.
34. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. 2003. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24:1067-1075.
35. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S. 2004. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6:390-400.
36. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB. 2002. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52:183-200.
37. Vu TK, Hung DT, Wheaton VI, Coughlin SR. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068.
38. Walz DA, Fenton JW. 1994. The role of thrombin in tumor cell metastasis. Invasion Metastasis 14:303-308.
39. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, Mammen EF, Honn KV. 1993. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 54:793-806.
40. Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM. 2003. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 278: 25872-25878.
41. Yin YJ, Salah Z, Grisaru-Granovsky S, Cohen I, Even-Ram SC, Maoz M, Uziely B, Peretz T, Bar-Shavit R. 2003. Human protease-activated receptor 1 expression in malignant epithelia: A role in invasiveness. Arterioscler Thromb Vasc Biol 23:940-944.
42. Yuan H, Liddle FJ, Mahajan S, Frank DA. 2004. IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. Carcinogenesis 25:2247-2255.
43. Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. 2000. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95:3133-3138.
44. Zerbini LF, Wang Y, Cho JY, Libermann TA. 2003. Constitutive activation of nuclear factor kappaB p50/ p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63:2206-2215.